Result Summaries: GSK256066
| GSK Study ID |
Phase | Title | Summary (Download) |
|---|---|---|---|
| IPR110723 | Phase 2 | An 8 day, randomised, double blind, 3-way crossover trial of repeat doses of intranasal GSK256066 and fluticasone propionate in the Vienna Challenge Chamber in subjects with seasonal allergic rhinitis (SAR) (0 citation(s)) |  |